BIVI - Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26 | Benzinga
CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is pleased to invite investors to a webinar on June 26, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease.
BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNF? production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function with lowered amyloid ? and p-tau levels, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels.
The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new ...